Core Viewpoint - Pro Pharmaceutical Co., Ltd. announced that its subsidiary, Zhejiang Pro Kangyu Pharmaceutical Co., Ltd., has received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration [2] Group 1 - The announcement was made on the evening of November 20 [2] - The drug registration certificate is a significant regulatory milestone for the company [2] - Cefdinir is an antibiotic used to treat various bacterial infections, indicating potential market opportunities for the company [2]

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

Group 1 - Prolo Pharmaceutical Co., Ltd. announced that its subsidiary, Zhejiang Prolo Kangyu Pharmaceutical Co., Ltd., received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration [1] - For the first half of 2025, Prolo Pharmaceutical's revenue composition is 99.6% from the pharmaceutical industry and 0.4% from other businesses [1] - As of the report date, Prolo Pharmaceutical has a market capitalization of 18.1 billion yuan [1]

Core Viewpoint - Pro Pharmaceutical Co., Ltd. has received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Group 1: Company Developments - The company’s subsidiary, Zhejiang Pro Pharmaceutical Co., Ltd., is the entity that received the drug registration certificate for Cefdinir capsules [1] - Cefdinir capsules are indicated for infections caused by various bacteria, including Staphylococcus, Streptococcus, and Escherichia coli, among others [1] Group 2: Product Indications - The indications for Cefdinir capsules include infections such as pharyngitis, tonsillitis, acute bronchitis, pneumonia, otitis media, sinusitis, pyelonephritis, cystitis, and gonococcal urethritis [1] - Additional indications cover conditions like pelvic inflammatory disease, intrauterine infections, and various skin and soft tissue infections [1]

Core Viewpoint - Pro Pharmaceutical Co., Ltd. has received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1]. Group 1 - Pro Pharmaceutical's subsidiary, Zhejiang Pro Kangyu Pharmaceutical Co., Ltd., is the entity that received the drug registration certificate [1].

证券代码：000739 证券简称：普洛药业 公告编号：2025-68 普洛药业股份有限公司 关于获得药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，普洛药业股份有限公司（以下简称"公司"）控股子公司浙江普洛康 裕制药有限公司收到国家药品监督管理局（以下简称"药监局"）签发的头孢地 尼胶囊《药品注册证书》。现将有关情况公告如下： 一、药品注册批准情况 1、产品名称：头孢地尼胶囊 2、剂型：胶囊剂 3、规格：0.1g 7、证书编号：2025S03340 8、药品批准文号：国药准字 H20255880 9、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 头孢地尼胶囊，适应症为对头孢地尼敏感的葡萄球菌属、链球菌属、肺炎球 菌、消化链球菌、丙酸杆菌、淋病奈瑟氏菌、卡他莫拉菌、大肠埃希菌、克雷伯 菌属、奇异变形杆菌、普鲁威登斯菌属、流感嗜血杆菌等菌株所引起的下列感染: 咽喉炎、扁桃体炎、急性支气管炎、肺炎；中耳炎、鼻窦炎；肾盂肾炎、膀胱炎、 淋菌性尿道 ...

Core Viewpoint - Prolo Pharmaceutical (000739.SZ) announced that its subsidiary, Zhejiang Prolo Kangyu Pharmaceutical Co., Ltd., has received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration [1] Group 1: Product Information - Cefdinir capsules are indicated for infections caused by bacteria sensitive to Cefdinir, including strains of Staphylococcus, Streptococcus, and others [1] - The specific infections treated by Cefdinir capsules include pharyngitis, tonsillitis, acute bronchitis, pneumonia, otitis media, sinusitis, pyelonephritis, cystitis, gonococcal urethritis, and various skin and soft tissue infections [1]

Core Viewpoint - Pro Pharmaceutical Co., Ltd. has received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration, indicating a significant regulatory milestone for the company [1] Group 1: Company Developments - The subsidiary Zhejiang Pro Kangyu Pharmaceutical Co., Ltd. is responsible for the newly approved Cefdinir capsules [1] - Cefdinir is indicated for various infections caused by sensitive strains of bacteria, including Streptococcus, Staphylococcus, and Escherichia coli, among others [1] Group 2: Product Indications - The approved indications for Cefdinir capsules include infections such as pharyngitis, tonsillitis, acute bronchitis, pneumonia, otitis media, sinusitis, pyelonephritis, cystitis, and gonococcal urethritis [1] - Additional indications cover conditions like pelvic inflammatory disease, intrauterine infections, and various skin and soft tissue infections [1]

Core Viewpoint - Pro Pharmaceutical announced that its subsidiary, Zhejiang Pro Kangyu Pharmaceutical Co., Ltd., received a drug registration certificate for Cefdinir capsules, which is classified as a Class 4 chemical drug, indicating a significant step in expanding its market presence and competitiveness in the pharmaceutical industry [1] Group 1: Drug Registration and Market Potential - The drug registration certificate is for Cefdinir capsules with a specification of 0.1g, which is expected to have a wide range of indications [1] - The estimated market size for the drug in China's hospital market for 2024 is projected to be 380 million capsules, with a sales value of 310 million yuan [1] - The total R&D investment for this drug has reached 5.2818 million yuan as of the announcement date [1] Group 2: Competitive Advantage and Market Factors - The approval of the drug registration certificate is considered equivalent to passing the consistency evaluation, which is expected to enhance sales and improve competitive positioning [1] - However, the production and sales of the drug may be influenced by various factors, including policies and market conditions [1]

Core Viewpoint - Pro Pharmaceutical announced that its subsidiary, Zhejiang Pro Pharmaceutical Co., Ltd., has received a drug registration certificate for Cefdinir capsules from the National Medical Products Administration [1] Group 1: Product Information - Cefdinir capsules are indicated for infections caused by various bacteria, including Staphylococcus, Streptococcus, Pneumococcus, and others [1]